secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2024-04-05T23:59:59+00:00
Accession:  0000950170-24-042288
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum Therapeutics receives Nasdaq delisting notice for equity deficit of $6.4M
--------------------------------------------------------------------------------

- Stockholders' equity deficit of $6.4M as of Dec 31, 2023, below Nasdaq's $2.5M minimum.
- Company must submit a compliance plan by May 20, 2024; Nasdaq may extend deadline to Sept 30, 2024.
- If plan is rejected or compliance not regained, delisting proceedings may begin with appeal rights.
- Iterum is evaluating options to resolve the deficiency; listing continues for now.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024042288/0000950170-24-042288-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024042288/itrm-20240403.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-042288

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer